<DOC>
	<DOCNO>NCT02787304</DOCNO>
	<brief_summary>The purpose study determine investigational treatment volixibat ( SHP626 ) safe , tolerable effective adult nonalcoholic steatohepatitis ( NASH ) .</brief_summary>
	<brief_title>Volixibat ( SHP626 ) Treatment Adults With Nonalcoholic Steatohepatitis ( NASH )</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Bile Acids Salts</mesh_term>
	<criteria>1 . Male , nonpregnant , nonlactating female sexually active agrees comply contraceptive requirement protocol female nonchildbearing potential . 2 . Presence ≥ 5 % steatosis screen MRI centrally read radiologist perform either screening period within 6 month prior first visit . 3 . Histologic confirmation NASH without cirrhosis ( fibrosis stage 1 , 2 , 3 ) centrally read liver biopsy perform either screening period within 6 month prior first visit NAS ≥ 4 score least 1 component ( steatosis , lobular inflammation , hepatocyte ballooning ) . 1 . Presence history cirrhosis evidence decompensated liver disease hepatocellular carcinoma 2 . History presence concomitant liver disease assess investigator determine laboratory finding 3 . Current recurrent disease could affect action , absorption , disposition , laboratory assessment IP ( include bile salt metabolism intestine ) 4 . Weight change ≥5 % qualify liver biopsy and/or MRI perform . If subject liver biopsy and/or MRI within 6 month screen , experienced weight change ≥5 % since date liver biopsy and/or MRI , liver biopsy and/or MRI must repeat screening . 5 . Inability MRI ( ie , claustrophobia , coronary stent , coronary implantable device , girth , etc. ) . 6 . Current relevant history physical psychiatric illness , medical disorder may require treatment make subject unlikely complete study . 7 . Uncontrolled diabetes define HbA1c ≥ 9.0 % within 60 day prior enrollment . 8 . Current use medication ( include overthecounter , herbal , homeopathic preparation ) could affect action , absorption , disposition IP , clinical laboratory assessment . 9 . Use drug , herb supplement historically associate cause worsen NAFLD/NASH le 6 month prior qualify liver biopsy , initiated time qualify liver biopsy perform , include use total parenteral nutrition ( TPN ) . 10 . Serum AST &gt; 5 time upper limit normal ( ULN ) screening . 11 . Serum ALT &gt; 5 time ULN screening . 12 . Elevated serum creatinine ≥ 2.0 mg/dL . 13. International normalize ratio ( INR ) &gt; 1.3 . 14 . Total bilirubin ( TB ) ≥ 2.0 x ULN screening ( Except document Gilbert 's syndrome bilirubin level 20 µmol/L 90 µmol/L ( 1.2 5.3 mg/dL ) ratio unconjugated/conjugated bilirubin commensurately high ) . 15 . Platelet count &lt; 130 × 109L 16 . Medical history impaired hemostasis use anticoagulant medication ( use antiplatelet medication , lowdose , ie 81mg aspirin ( ASA ) clopidogrel ( Plavix ) allow ) . 17 . Uncontrolled thyroid disease . 18 . Type 1 diabetes mellitus . 19 . Known suspected intolerance hypersensitivity IP , closelyrelated compound , state ingredient . 20 . Known history alcohol substance abuse within last year . Weekly alcohol intake great 21 grams/day male 14 grams/day female average inability reliably quantify alcohol consumption base investigator 's judgment . 21 . Inability safely obtain liver biopsy . 22 . The anticipated need surgical procedure study could interfere treatment . 23 . Known positivity human immunodeficiency virus ( HIV ) infection . 24 . Cancer within 5 year screen , except basal squamous cell carcinoma skin situ cervical carcinoma treat evidence recurrence . 25 . History noncompliance medical regimen , unreliability , mental instability incompetence could compromise validity inform consent lead noncompliance study protocol . 26 . Any condition abnormality , opinion investigator , may compromise safety subject , interfere subject participating . 27 . Subject fail screen previously enrol study currently enrol study study site ( unless subject transfer another qualify study site prior Sponsor approval ) . 28 . Females pregnant , plan become pregnant , breastfeeding , male plan father child study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>NAFLD activity score</keyword>
	<keyword>ASBTi</keyword>
	<keyword>MRI PDFF</keyword>
	<keyword>NAS</keyword>
	<keyword>NAFLD</keyword>
	<keyword>liver disease</keyword>
	<keyword>ASBT</keyword>
	<keyword>MRI proton density fat fraction</keyword>
	<keyword>nonalcoholic steatohepatitis</keyword>
	<keyword>apical sodium dependent bile acid transporter inhibitor</keyword>
	<keyword>fatty liver</keyword>
	<keyword>NASH</keyword>
</DOC>